[
  {
    "ts": null,
    "headline": "Top 50 High-Quality Dividend Growth Stocks For April 2025",
    "summary": "8 high-quality dividend stocks with top return potential for 2025. Click here for a detailed analysis.",
    "url": "https://finnhub.io/api/news?id=7e164db62b82712493c6c3ac3658c57e9cc854ca8b7bd166867e1c6f8ba49c6d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743722900,
      "headline": "Top 50 High-Quality Dividend Growth Stocks For April 2025",
      "id": 133701527,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165465384/image_2165465384.jpg?io=getty-c-w1536",
      "related": "RMD",
      "source": "SeekingAlpha",
      "summary": "8 high-quality dividend stocks with top return potential for 2025. Click here for a detailed analysis.",
      "url": "https://finnhub.io/api/news?id=7e164db62b82712493c6c3ac3658c57e9cc854ca8b7bd166867e1c6f8ba49c6d"
    }
  },
  {
    "ts": null,
    "headline": "ResMed (NYSE:RMD) Launches NightOwl Device to Simplify Home Sleep Apnea Testing Across US",
    "summary": "ResMed (NYSE:RMD) launched NightOwl™, a home sleep apnea test that enhances user convenience with a small fingertip sensor and cloud data evaluation. Despite the broader market reacting negatively to new tariffs announced by President Trump—causing significant declines across major indexes like the Dow Jones and S&P 500—ResMed's stock remained relatively flat over the past week. The stable performance may reflect investor confidence in the potential of its innovative health solutions,...",
    "url": "https://finnhub.io/api/news?id=3084e4c6989b4ae8a13ef28af7fd228a7237a991d90866d5d5ca81530ec06ff8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743701322,
      "headline": "ResMed (NYSE:RMD) Launches NightOwl Device to Simplify Home Sleep Apnea Testing Across US",
      "id": 133699156,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "ResMed (NYSE:RMD) launched NightOwl™, a home sleep apnea test that enhances user convenience with a small fingertip sensor and cloud data evaluation. Despite the broader market reacting negatively to new tariffs announced by President Trump—causing significant declines across major indexes like the Dow Jones and S&P 500—ResMed's stock remained relatively flat over the past week. The stable performance may reflect investor confidence in the potential of its innovative health solutions,...",
      "url": "https://finnhub.io/api/news?id=3084e4c6989b4ae8a13ef28af7fd228a7237a991d90866d5d5ca81530ec06ff8"
    }
  },
  {
    "ts": null,
    "headline": "ResMed Inc. stock falls Thursday, still outperforms market",
    "summary": "ResMed Inc. stock falls Thursday, still outperforms market",
    "url": "https://finnhub.io/api/news?id=c5b9bc8a51babd7fce359ae8ca4e2d3eeb3a3c150807fcb0118b33222e09c414",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743699300,
      "headline": "ResMed Inc. stock falls Thursday, still outperforms market",
      "id": 133716146,
      "image": "",
      "related": "RMD",
      "source": "MarketWatch",
      "summary": "ResMed Inc. stock falls Thursday, still outperforms market",
      "url": "https://finnhub.io/api/news?id=c5b9bc8a51babd7fce359ae8ca4e2d3eeb3a3c150807fcb0118b33222e09c414"
    }
  },
  {
    "ts": null,
    "headline": "ResMed Inc. (RMD): A Bull Case Theory",
    "summary": "We came across a bullish thesis on ResMed Inc. (RMD) on Substack by LongTermValue Research. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc. (RMD)’s share was trading at $223 as of April 2nd. RMD’s trailing and forward P/E were 26.33 and 21.79 respectively according to Yahoo Finance. ResMed (RMD), a $32.5 billion […]",
    "url": "https://finnhub.io/api/news?id=57feedde8a40677a3e9ef9d6d03f5d49a5d87b7c7e45391fa1037866391ef71d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743687709,
      "headline": "ResMed Inc. (RMD): A Bull Case Theory",
      "id": 133697986,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on ResMed Inc. (RMD) on Substack by LongTermValue Research. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc. (RMD)’s share was trading at $223 as of April 2nd. RMD’s trailing and forward P/E were 26.33 and 21.79 respectively according to Yahoo Finance. ResMed (RMD), a $32.5 billion […]",
      "url": "https://finnhub.io/api/news?id=57feedde8a40677a3e9ef9d6d03f5d49a5d87b7c7e45391fa1037866391ef71d"
    }
  },
  {
    "ts": null,
    "headline": "Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US",
    "summary": "FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing and diagnosisSAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplifie",
    "url": "https://finnhub.io/api/news?id=62d0364c9f4eab3787e7e89287c9b15fb41ea8112fc382f9fe4190a52497b362",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743685200,
      "headline": "Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US",
      "id": 133697988,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing and diagnosisSAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplifie",
      "url": "https://finnhub.io/api/news?id=62d0364c9f4eab3787e7e89287c9b15fb41ea8112fc382f9fe4190a52497b362"
    }
  }
]